Interesting thanks for sharing. I cut down my stack pretty substantially recently. Piracetam in itself barely has an effect on me anymore. For me, Phenotropil 100mg seems to work quite well when i take it occasionally but it disrupts my sleep a bit even when i take i early in the morning. It just clears my mind and makes me more attentive and focused.
I also inject IM Cortexin which I started to love, and Cerebrolysin .
I also drink 5mg of Methylene blue + vit c or I just get Methylene blue + Vit C in an IV twice a week.
Interestingly coffee in itself really has no effect on me and actually causes me to be exhausted shortly after. But when I supplement with caffeine in other forms, I always take it with L-theanine to reduce jitters and that works well.
Also as an anxiolytic, I found nothing really beats L-theanine for an immediate effect.
If your taking nicotine in any form , i would supplement with large doses of thiamine given that it heavily depletes thiamine.
The mouse dose was 2 μg/mL in drinking water from 6 to 12 months, which restored NAMPT activity and NAD+ in brain, heart, and muscle. Critically: high-dose nicotine had the opposite effect on NAMPT. NAD
A 2025 Advanced Science paper extended this, finding long-term oral nicotine in mice protected against motor decline with age, and NAMPT expression was significantly increased in muscle tissue. Wiley Online Library
The dose translation problem: 2 μg/mL in mouse drinking water is roughly 0.2–0.4 mg/kg/day depending on water consumption. The human equivalent after standard allometric scaling is probably in the range of ~1–3 mg/day total nicotine exposure. A 2mg lozenge gives you a peak plasma Cmax somewhere around 5–8 ng/mL dropping over an hour; a 4mg lozenge roughly doubles that. Whether the tissue concentrations achieved match the mouse “low dose” threshold — and crucially, whether you stay below the high-dose zone that reverses the NAMPT effect — is genuinely unknown and I’d be speculating to give you a number with confidence.
Mechanism 2 — nAChR agonism (the cognitive/Alzheimer angle)
This is completely separate from NAD and has far more human data. Newhouse’s 2012 pilot trial — 15mg/day transdermal nicotine for 6 months in nonsmoking MCI patients — showed 46% recovery toward normal age performance on long-term memory, while placebo worsened by 26%. PubMed
The larger follow-up MIND study (Vanderbilt, 29 sites) enrolled ~300 MCI patients for a 2-year trial of transdermal nicotine patches starting at 7mg/day and scaling to 21mg/day. Results from that should be out or close to out — I don’t have the final data in my search results, which is a gap worth noting.
I tried experimenting with nicotine patches in small doses 0.5-4mg and had asthmatic/allergic reactions. Removing the patch caused the symptoms to stop in a few hours.